Treatment of donor-specific antibody-mediated rejection after heart transplantation by IgM-enriched human immunoglobulin

被引：3
|
作者：
Immohr, Moritz Benjamin [1 ]
Akhyari, Payam [1 ]
Aubin, Hug [1 ]
Westenfeld, Ralf [2 ]
Mehdiani, Arash [1 ]
Bruno, Raphael Romano [2 ]
Sipahi, Nihat Firat [1 ]
Erbel-Khurtsidze, Sophiko [1 ]
Reinecke, Petra [3 ]
Tudorache, Igor [1 ]
Lichtenberg, Artur [1 ]
Boeken, Udo [1 ]
机构：
[1] Heinrich Heine Univ, Med Sch, Med Fac, Dept Cardiac Surg, Moorenstr 5, D-40225 Dusseldorf, Germany
[2] Heinrich Heine Univ, Med Sch, Dept Cardiol Pulmonol & Vasc Med, Dusseldorf, Germany
[3] Heinrich Heine Univ, Med Sch, Inst Pathol, Dusseldorf, Germany
来源：
ESC HEART FAILURE | 2021年 / 8卷 / 04期
关键词：
Heart transplantation; Antibody mediated rejection; Immunoglobulin; IgM; Donor specific antibody;
D O I：
10.1002/ehf2.13409
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Antibody-mediated graft rejection caused by donor-specific antibodies (DSA-MR) remains a serious problem after heart transplantation (HTx). IgM-enriched human intravenous immunoglobulin (IGM-IVIG) consists of 76% IgG, 12% IgM, and 12% IgA and provides a new multifactorial approach for DSA-MR. Between 2017 and 2020, four (P1-4) of 102 patients developed DSA-MR after HTx in our department and were repetitively treated with IGM-IVIG in combination with anti-thymocyte globulin. While in P1 and P4, DSA-MR occurred within the early post-operative interval, P2 and P3 developed DSA-MR approximately 1 year after transplantation. An impairment of ventricular function was observed in three of four patients. Furthermore, P1 and P4 suffered from malign ventricular arrhythmias. After the application of IGM-IVIG, the ventricular function recovered, and all patients could be discharged from the hospital. As part of a multifactorial therapeutic approach, treatment with IGM-IVIG seems to be a safe and effective strategy to address DSA-MR.
引用
收藏
页码：3413 / 3417
页数：5
相关论文
共 50 条
  • [41] How Does Donor Specific Antibody Relate to Biopsy-diagnosed Antibody-mediated Rejection after Pediatric Heart Transplantation?
    Ware, A.
    Snow, G.
    Hammond, E.
    Miller, D. V.
    Stehlik, J.
    Kfoury, A. G.
    Eckhauser, A.
    Eckels, D.
    Everitt, M.
    [J]. JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2014, 33 (04): : S123 - S124
  • [42] Antibody-mediated rejection owing to donor-specific HLA-DQA1 antibodies after renal transplantation: A case report
    Liu, Wei
    Kang, Zhong-Yu
    Wang, Zheng-Lu
    Li, Dai-Hong
    [J]. TRANSPLANT IMMUNOLOGY, 2022, 73
  • [43] Risk Factors for Antibody-Mediated Rejection after Adult Liver Transplantation with Preformed Donor-Specific Antibodies: A Single Center Experience
    Tajima, T.
    Hata, K.
    Kusakabe, J.
    Miyauchi, H.
    Anazawa, T.
    Ito, T.
    Uemoto, S.
    [J]. AMERICAN JOURNAL OF TRANSPLANTATION, 2020, 20 : 495 - 495
  • [44] Long-term Results of an IgM-enriched Human Immunoglobulin-based Therapy for Early Donor Specific Antibodies After Lung Transplantation
    Ius, F.
    Sommer, W.
    Verboom, M.
    Hallensleben, M.
    Salman, J.
    Siemeni, T.
    Kuehn, C.
    Avsar, M.
    Bobylev, D.
    Poyanmehr, R.
    Schwerk, N.
    Mueller, C.
    Haverich, A.
    Tudorache, I.
    Warnecke, G.
    [J]. JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2018, 37 (04): : S109 - S110
  • [45] Influence of an IgM-enriched Intravenous Immunoglobulin-based Treatment on Regulatory T Cells in Patients with Donor Specific Antibodies After Lung Transplantation
    Ius, F.
    Sommer, W.
    Knoefel, A.
    Salman, J.
    Nakagiri, T.
    Siemeni, T.
    Kuehn, C.
    Avsar, M.
    Bobylev, D.
    Poyanmehr, R.
    Welte, T.
    Haverich, A.
    Tudorache, I.
    Warnecke, G.
    [J]. JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2018, 37 (04): : S89 - S89
  • [46] Donor-specific antibodies are associated with antibody-mediated rejection, acute cellular rejection, bronchiolitis obliterans syndrome, and cystic fibrosis after lung transplantation
    Lobo, Leonard J.
    Aris, Robert M.
    Schmitz, John
    Neuringer, Isabel. P.
    [J]. JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2013, 32 (01): : 70 - 77
  • [47] Accelerated De-Novo Donor-Specific Antibody-Mediated Rejection in a Non-Human Primate Model of Renal Transplantation
    Danobeitia, J.
    Chlebeck, P.
    Torrealba, J.
    Zens, T.
    Zitur, L.
    D'Alessandro, A.
    Fernandez, L.
    [J]. AMERICAN JOURNAL OF TRANSPLANTATION, 2017, 17 : 616 - 617
  • [48] TIMING OF DONOR-SPECIFIC HLA ANTIBODY TESTING IN THE DIAGNOSIS OF ANTIBODY-MEDIATED REJECTION IN KIDNEY ALLOGRAFTS
    Kaneku, H.
    Mateu, D.
    Fernandez-Bango, C.
    Ruiz, P.
    [J]. HUMAN IMMUNOLOGY, 2022, 83 : 113 - 113
  • [49] Antibody-mediated rejection - a major complication after heart transplantation
    Sandra Maria Resende Amorim, S.
    Rodrigues Pereira, P.
    Pinto, R.
    Araujo, P.
    Tafulo, S.
    Garcia, R.
    Andrade, M.
    Pinheiro Torres, J.
    Silva Cardoso, J.
    Macedo, F.
    Pinho, P.
    [J]. EUROPEAN JOURNAL OF HEART FAILURE, 2023, 25 : 219 - 219
  • [50] Antibody-Mediated Rejection is Associated with Microvasculopathy after Heart Transplantation
    Hiemann, Nicola E.
    Wellnhofer, Ernst
    Kretschmer, Sophie
    Christan, Claudia
    Hetzer, Roland
    Meyer, Rudolf
    [J]. CIRCULATION, 2012, 126 (21)
12345